EXCELLENT CLINICAL AND PHARMACOKINETIC REAL-WORLD EXPERIENCE AFTER SWITCHING TO DAMOCTOCOG ALFA PEGOL

被引：0
|
作者：
Hidalgo, O. Benitez [1 ]
Gimenez, J. C. Juarez [2 ]
机构：
[1] Vall Hebron Univ Vall, Hemophilia Unit, Hematol Dept, Barcelona, Spain
[2] Vall Hebron Univ Vall, Pharm Deparment, Barcelona, Spain
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO048
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [31] Real-world effectiveness and safety of damoctocog alfa pegol in patients with haemophilia A and a history of factor VIII inhibitors: A post-hoc analysis of the ongoing HEM-POWR study
    Reding, Mark
    Alvarez-Roman, Maria Teresa
    Castaman, Giancarlo
    Janbain, Maissaa
    Matsushita, Tadashi
    Meijer, Karina
    Schmidt, Kathrin
    Oldenburg, Johannes
    HAEMOPHILIA, 2024, 30 : 34 - 35
  • [32] UNDERSTANDING THE REAL-WORLD EXPERIENCE OF PEOPLE WITH HAEMOPHILIA A RECEIVING TUROCTOCOG ALFA PEGOL (N8-GP): RESULTS FROM A PATIENT EXPERIENCE SURVEY
    Eichler, H.
    Nagao, A.
    Waller, J.
    Stuber, A.
    VALUE IN HEALTH, 2022, 25 (12) : S437 - S437
  • [33] Real-World Experience after Switching to FIX Extended Half Life Using Pharmacokinetic Poblacional Software and One- Compartimental MODEL
    Benitez Hidalgo, Olga
    Juarez Gimenez, Juan Carlos
    Alvarez Roman, Maria Teresa
    Romero Garrido, Jose Antonio
    Gomez Del Castillo, Maria Del Carmen
    Gonzalez Pineiro, Sara
    Olivera, Pavel E.
    Bosch, Francesc
    Bruno Montoro, Jose
    BLOOD, 2022, 140 : 11301 - 11301
  • [34] Real-world utilization of andexanet alfa
    Brown, Caitlin S.
    Scott, Rachael A.
    Sridharan, Meera
    Rabinstein, Alejandro A.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2020, 38 (04): : 810 - 814
  • [35] CLINICAL OUTCOMES FOLLOWING PROPHYLAXIS WITH RURIOCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A: REAL-WORLD OBSERVATIONAL DATA FROM THE AHEAD INTERNATIONAL STUDY
    Ozelo, M. C.
    Hermans, C.
    Khair, K.
    Guillet, B.
    Guerra, R.
    Gu, J.
    Tang, L.
    Carcao, M.
    HAEMOPHILIA, 2022, 28 : 45 - 45
  • [36] Switching antiplatelet therapy in real-world clinical practice
    Angiolillo, Dominick J.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2018, 19 (08) : 897 - 898
  • [37] Real-World Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data
    Watt, Maureen
    Milligan, Scott
    BLOOD, 2019, 134
  • [38] Patients in the Pompe registry who switched from alglucosidase alfa to avalglucosidase alfa: Real-world experience
    Schoser, B.
    Toscano, A.
    Foster, M.
    Periquet, M.
    Sparks, S.
    Kishnani, P.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S152 - S152
  • [39] Patients in the Pompe Registry who switched from alglucosidase alfa to avalglucosidase alfa: Real-world experience
    Schoser, B.
    Abbott, M.
    Toscano, A.
    Foster, M.
    Periquet, M.
    Sparks, S.
    Kishnani, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 572 - 573
  • [40] CLINICAL OUTCOMES IN PATIENTS WITH HAEMOPHILIA A AFTER SWITCHING TO RURIOCTOCOG ALFA PEGOL PROPHYLAXIS IN THE ATHN 2 STUDY
    Journeycake, J.
    Caicedo, J.
    Cheng, D.
    Denne, M.
    Guelcher, C.
    Lattimore, S.
    Mokdad, A.
    Ragni, M.
    Recht, M.
    Sidonio, R., Jr.
    Takemoto, C.
    Tarantino, M. D.
    Watson, C. W. Crystal
    Neufeld, E.
    HAEMOPHILIA, 2021, 27 : 55 - 56
12345